Pursuant to Article 241-2 of the AMF General Regulations (Reglement General de l'Autorite des marches financiers), the purpose of this description is to present the objectives and terms of the share repurchase program of Inventiva S.A. (the 'Company') as approved by the Ordinary General Meeting.
Securities concerned: shares issued by Inventiva S.A. ? Maximum proportion of capital that may be purchased by the Company: 10% of the total number of shares comprising the share capital at any time. ? Maximum number of its own shares that may be acquired by the Company, based on the number of shares making up the share capital as of April 30, 2022: 4,087,355; however, taking into account the 64,401 shares held in treasury, only 4,022,954 treasury shares are available to be acquired. ? Allocation of treasury shares as of April 30, 2022: the 64,401 treasury shares held as of April 30, 2022, are allocated to ensure the liquidity of, or making the market in, Inventiva's shares through intermediation of an investment services provider acting independently within the framework of a market making agreement that complies with a code of conduct recognized by the Autorite des marches financiers. ? Maximum price per share: 40 euros.
Objectives:
The objectives of the share repurchase program pursuant to the 19th resolution of the Ordinary General Meeting of May 19, 2022 are: - to purchase or sell shares under a liquidity agreement entered into with an investment services provider, in accordance with the conditions set by the market authorities; - to implement and perform obligations related to stock option programs or other share allocations to employees and officers of the Company and, in particular, to allocate shares to employees and corporate officers of the Company in connection with (i) profit-sharing, or (ii) any share purchase, stock option or free share allocation plan under the conditions provided for by law, in particular by Articles L.3331- 1 seq. of the French Labor Code (including any sale of shares referred to in Article L.3332-24 of the French Labor Code), and to carry out any hedging transactions relating to such transactions; to deliver ordinary shares upon the exercise of rights attached to securities carrying rights to shares of the Company by redemption, conversion, exchange, presentation of a warrant or any other means; - to reduce the Company's share capital by cancelling all or some of the shares acquired; and - more generally, to carry out any transaction that may be authorized by law or any market practice that may be admitted by the market authorities, it being specified that, in such a case, the Company would inform its shareholders by means of a press release.
About Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of NASH and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva's lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies.
The Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases that resulted in the discovery of the drug candidate cedirogant (ABBV-157), an oral ROR? inverse agonist which is being evaluated in a Phase IIb clinical trial, led by AbbVie, in adult patients with moderate to severe chronic plaque psoriasis. Inventiva's pipeline also includes odiparcil, a drug candidate for the treatment of adult mucopolysaccharidoses (MPS) VI patients. As part of Inventiva's decision to focus clinical efforts on the development of lanifibranor, it suspended clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program.
The Company has a scientific team of approximately 80 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.
Contact:
Westwicke
ICR Company
Patricia L. Bank
Investor relations
E: patti.bank@westwicke.com
T: +1 415 513-1284
INVENTIVA 
